查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1518493

雄性秃治疗市场- 按治疗类型（药物{局部、口服}、设备{激光帽、梳子、头盔}）、按性别（男性、女性）、按药物类型（处方药、非处方药）、按最终用途和预测, 2024 - 2032

Androgenetic Alopecia Treatment Market - By Treatment Type (Pharmaceutical {Topical, Oral}, Device {Laser Cap, Comb, Helmet}), By Gender (Male, Female), By Medication Type (Prescription, OTC), By End-use & Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在该领域临床试验和研发进步的推动下，2024 年至 2032 年间，全球雄性秃治疗市场的复合年增长率将达到 7.6%。 AGA，俗称男性或女性型秃髮，影响着全球数百万人，为有效治疗创造了庞大的市场。近年来，突破性的研究催生了新的治疗方法。例如，2024 年 1 月，HopeMed 将其雄性秃治疗推进到 II 期试验。这家中国製药公司在其催乳素受体抗体在一期研究中取得积极成果后启动了二期招募。该医院最近开始招募 II 期试验，以评估其单株抗体 HMI-115 治疗雄性秃的效果。

先进的临床试验正在探索创新的解决方案，包括基因疗法、干细胞疗法和针对脱髮潜在机制的新型药物製剂。对 AGA 所涉及的遗传和分子途径的日益深入的了解为标靶治疗铺平了道路，为更有效和个性化的治疗带来了希望。此外，生物技术和医疗技术的进步正在提高这些治疗的精确度和功效。随着研究的不断进展，更有效率、更安全、更持久的 AGA 解决方案的承诺正在推动这一充满活力的领域的需求和投资不断增加。

整体雄性秃治疗行业规模根据治疗类型、性别、药物类型、最终用途和地区进行分类。

该设备领域将在 2024 年至 2032 年经历严格的发展。这些设备为传统药物治疗提供了便捷的替代方案，吸引了寻求有效且用户友好的解决方案的个人。此外，设备技术的不断创新提高了治疗效果，使其成为脱髮男性和女性的有吸引力的选择。因此，AGA 治疗设备的市场不断扩大，满足了对有效头髮修復方法不断增长的需求。

从 2024 年到 2032 年，女性部分的雄性秃治疗市场收入将出现显着的复合年增长率。随着越来越多的女性寻求有效的解决方案，市场已经推出了适合女性需求的治疗方法，包括局部解决方案、口服药物以及富血小板血浆(PRP) 和低强度雷射疗法(LLLT) 等先进疗法。此外，专门针对女性脱髮的研究的增长带来了更有效、更有针对性的治疗方法，进一步刺激了需求。这一转变反映出人们越来越认识到解决女性 AGA 问题的重要性。

欧洲雄性秃治疗市场将在 2024 年至 2032 年呈现出值得称讚的复合年增长率。这包括局部米诺地尔、口服非那雄胺以及富血小板血浆 (PRP) 疗法和低强度雷射疗法 (LLLT) 等新选择。欧洲市场对尖端研究和开发的重视带来了更有效、个人化的治疗选择。此外，社会转向优先考虑外表和福祉，这导致整个非洲大陆对 AGA 治疗的需求不断增长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 雄性秃盛行率上升
      • 治疗技术进步
      • 人们对脱髮治疗方案的认识不断提高
    • 产业陷阱与挑战
      • 治疗费用高
  • 成长潜力分析
  • 监管环境
  • 报销场景
  • 技术景观
  • 启动场景
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按治疗类型，2021 - 2032 年

  • 主要趋势
  • 製药
    • 专题
    • 口服
  • 装置
    • 雷射帽
    • 雷射梳
    • 雷射头盔
  • 其他治疗类型

第 6 章：市场估计与预测：按性别划分，2021 - 2032 年

  • 主要趋势
  • 男性
  • 女性

第 7 章：市场估计与预测：按药物类型，2021 - 2032 年

  • 主要趋势
  • 处方
  • 场外交易

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 皮肤科诊所
  • 家庭护理设置
  • 其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • Apira Science, Inc. (iGROW Laser)
  • Aurobindo Pharma
  • Cipla, Inc.
  • Curallux, LLC
  • Dr. Reddy's Laboratories Ltd.
  • Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System)
  • Johnson & Johnson Services, Inc.
  • Lexington Intl., LLC
  • Merck & Co., Inc.
  • Theradome Inc.
简介目录
Product Code: 9219

Global Androgenetic Alopecia Treatment Market will witness 7.6% CAGR between 2024 and 2032, driven by advancements in clinical trials and research and development in the field. AGA, commonly known as male or female pattern baldness, affects millions worldwide, creating a substantial market for effective treatments. Recent years have seen groundbreaking research leading to novel therapeutic approaches. For instance, in January 2024, HopeMed advanced its androgenetic alopecia treatment to Phase II trials. The China-based pharmaceutical company initiated Phase II recruitment following the positive outcomes of its prolactin receptor antibody in a Phase I study. The hospital commenced recruitment for a Phase II trial to evaluate its monoclonal antibody HMI-115 for androgenetic alopecia recently.

Advanced clinical trials are exploring innovative solutions, including gene therapy, stem cell treatments, and novel pharmacological agents that target the underlying mechanisms of hair loss. The growing understanding of genetic and molecular pathways involved in AGA has paved the way for targeted therapies, offering hope for more effective and personalized treatments. Furthermore, advancements in biotechnology and medical technology are enhancing the precision and efficacy of these treatments. As research continues to progress, the promise of more efficient, safe, and long-lasting solutions for AGA is driving increased demand and investment in this dynamic field.

The overall androgenetic alopecia treatment Industry size is classified based on the treatment type, gender, medication type, end-use, and region.

The device segment will undergo rigorous development from 2024 to 2032. Devices such as low-level laser therapy (LLLT) caps, microneedling rollers, and scalp cooling systems have gained popularity due to their non-invasive nature and ease of use. These devices offer a convenient alternative to traditional pharmacological treatments, attracting individuals seeking effective and user-friendly solutions. Additionally, the continuous innovation in device technology enhances treatment efficacy, making them an appealing option for both men and women experiencing hair loss. As a result, the market for AGA treatment devices is expanding, meeting the growing demand for effective hair restoration methods.

The androgenetic alopecia treatment market revenue from the female segment will register a notable CAGR from 2024 to 2032. Traditionally considered a male issue, AGA affects a substantial number of women, causing distress and impacting self-esteem. As more women seek effective solutions, the market has responded with treatments tailored to female needs, including topical solutions, oral medications, and advanced therapies like platelet-rich plasma (PRP) and low-level laser therapy (LLLT). Additionally, the growth of research specifically focused on female hair loss has led to more effective and targeted treatments, further fueling demand. This shift reflects a growing recognition of the importance of addressing AGA in women.

Europe androgenetic alopecia treatment market will showcase a commendable CAGR from 2024 to 2032. European consumers are becoming more proactive about addressing hair loss, leading to higher adoption rates of both traditional and innovative treatments. This includes topical minoxidil, oral finasteride, and newer options like platelet-rich plasma (PRP) therapy and low-level laser therapy (LLLT). The European market's emphasis on cutting-edge research and development has led to more effective, personalized treatment options. Additionally, societal shifts towards prioritizing appearance and well-being are contributing to the growing demand for AGA treatments across the continent.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of androgenetic alopecia
      • 3.2.1.2 Technological advancements in treatment
      • 3.2.1.3 Growing awareness about alopecia treatment options
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of treatments
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Reimbursement scenario
  • 3.6 Technological landscape
  • 3.7 Start-up scenario
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Pharmaceutical
    • 5.2.1 Topical
    • 5.2.2 Oral
  • 5.3 Device
    • 5.3.1 Laser cap
    • 5.3.2 Laser comb
    • 5.3.3 Laser helmet
  • 5.4 Other treatment types

Chapter 6 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Male
  • 6.3 Female

Chapter 7 Market Estimates and Forecast, By Medication Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Prescription
  • 7.3 OTC

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Dermatology clinics
  • 8.3 Homecare settings
  • 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Apira Science, Inc. (iGROW Laser)
  • 10.2 Aurobindo Pharma
  • 10.3 Cipla, Inc.
  • 10.4 Curallux, LLC
  • 10.5 Dr. Reddy's Laboratories Ltd.
  • 10.6 Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System)
  • 10.7 Johnson & Johnson Services, Inc.
  • 10.8 Lexington Intl., LLC
  • 10.9 Merck & Co., Inc.
  • 10.10 Theradome Inc.